Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

doi:10.3748/wjg.v27.i25.3762

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5355)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

415

WORD

210

HTML

2877

Tables (1-4)

399

Sum=3901

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

649

Download

805

Sum=1454

Jul 7, 2021 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 7, 2021; 27(25): 3762-3779
Published online Jul 7, 2021. doi: 10.3748/wjg.v27.i25.3762

Table 4 Revaccination studies for hepatitis B virus in inflammatory bowel disease

Ref.	Study	Patients, n	Strategies	Response rate for anti-HBs
Pratt et al[71], 2019	Retrospective cohort	149	3-dose schedule vs 1 or 2 doses	62.9%
Pratt et al[71], 2019	Retrospective cohort	149	3-dose schedule vs 1 or 2 doses	40.2% (> 10)
Cossio-Gil et al[60], 2015	Retrospective cohort	53	3-dose schedule	52.8%
Loras et al[59], 2014	Prospective	389	Double-dose 0-1-2	31.3% (> 100)
Loras et al[59], 2014	Prospective	389	Double-dose 0-1-2	44.4% (10-100)

HBs: Hepatitis B surface protein.

Citation: Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779
URL: https://www.wjgnet.com/1007-9327/full/v27/i25/3762.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i25.3762